Latest news and press releases about Grace Therapeutics, Inc. (GRCE): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage.
Price
| Price | $2.14 |
| Market Cap | $35M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.75 |
| EV / EBITDA | -0.80 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -35.78% |
| Return on Invested Capital | -48.75% |
| Return on Assets | -42.84% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABVC · ATNM · CALC · LTRN · LVTX · OKUR · PDSB
Explore sector: Healthcare · Biotechnology
More sections of GRCE: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks